Рекомендации ISA, ISSAM, EAU, EAA и ASA: диагностика, лечение и мониторирование возрастногогипогонадизма у мужчин

1. Araujo A.B., Esche G.R., Kupelian V., O'donnell A.B., Travison T.G., Williams R.E., Clark R.V., McKinlay J.B. Prevalence of symptomatic androgen deficiency in men // J. Clin. Endocrinol. Metab., 2007; 92: 4241-4247.

2. Gray A., Feldman H.A., McKinlay J.B., Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study // J. Clin. Endocrinol. Metab., 1991; 73: 1016-1025.

3. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serumtotal and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. // J. Clin. Endocrinol. Metab., 2001; 86: 724-731.

4. Wu F.C., Tajar A., Pye S.R., Silman A.J., Finn J.D., O'Neill T.W., Bartfai G., Casanueva F., Forti G., Giwercman A., Huhtaniemi I.T., Kula K., Punab M., Boonen S., Vanderschueren D. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors // J. Clin. Endocrinol. Metab., 2008; 93: 2737-2745.

5. Liverman C.T., Blazer D.G. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2004.

6. sidori A.M., Giannetta E,. Gianfrilli D., Greco E.A., Bonifacio V., Aversa A., Isidori A., Fabbri A., Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis // Clin. Endocrinol. (Oxf.), 2005; 63: 381-394.

7. Isidori A.M., Giannetta E., Greco E.A., Gianfrilli D., Bonifacio V., Isidori A., Lenzi A., Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis // Clin. Endocrinol. (Oxf.), 2005; 63: 280-293.

8. Amory J.K., Watts N.B., Easley K.A., Sutton P.R., Anawalt B.D., Matsumoto A.M., Bremner W.J., Tenover J.L. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone // J. Clin. Endocrinol. Metab., 2004; 89: 503-510.

9. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., Tenover J.L. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T // J. Clin. Endocrinol. Metab., 2005; 90: 1502-1510.

10. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Lenrow D.A., Holmes J.H., Dlewati A., Santanna J., Rosen C.J., Strom B.L. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age // J. Clin. Endocrinol. Metab. 1999; 84: 2647-2653.

11. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Holmes J.H., Dlewati A., Staley J., Santanna J., Kapoor S.C., Attie M.F., Haddad J.G. Jr., Strom B.L. Effect of testosterone treatment on bone mineral density in men over 65 years of age // J. Clin. Endocrinol. Metab. 1999; 84: 1966-1972.

12. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Montori V.M. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab., 2006; 91: 1995-2010.

13. The Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male // Fertil. Steril., 2004; 81: 1437-1440.

14. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologist Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients - Update 2002. http://www.aace.com/pub/pdf/guidelines/hypogonadism.pdf; 2002.

15. Morales A., Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male // Aging. Male, 2002; 5: 74-86.

16. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu. F.C. Investigation, treatment andmonitoring of late-onset hypogonadism in Males. ISA, ISSAM, and EAU recommendations // Eur. Urol., 2005; 48: 1-4.

17. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu F.C. Investigation, treatment and monitoring of late-onset hypogonadism in males // Aging Male 2005; 8: 56-58.

18. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu F.C. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations // Int. J. Androl., 2005; 28: 125-127.

19. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu F.C. Investigation, treatment, andmonitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU Recommendations. J. Androl., 2006; 27: 135-137.

20. Morales A., Schulman C.C., Tostain J., Wu C.W. Testosterone Deficiency Syndrome (TDS) needs to be named appropriately - the importance of accurate terminology // Eur. Urol., 2006; 50: 407-409.

21. Schiavi R.C., Schreiner-Engel P., White D., Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men // Psychosom. Med., 1991; 53: 363-374.

22. Travison T.G., Morley J.E., Araujo A.B., O'Donnell A.B., McKinlay J.B. The relationship between libido and testosterone levels in aging men // J. Clin. Endocrinol. Metab., 2006; 91: 2509-2513.

23. Kelleher S., Conway A.J., Handelsman D.J. Blood testosterone threshold for androgen deficiency symptoms // J. Clin. Endocrinol. Metab., 2004; 89: 3813-3817.

24. Morales A., Spevack M., Emerson L., Kuzmarov I., Casey R., Black A., Tremblay R. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry // Aging Male, 2007; 10: 57-65.

25. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men // J. Clin. Endocrinol. Metab., 2006; 91: 4335-4343.

26. Heinemann L.A., Saad F., Heinemann K., Thai D.M. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? // Aging Male, 2004; 7: 211-218.

27. Moore C., Huebler D., Zimmermann T., Heinemann L.A., Saad F., Thai D.M. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency // Eur. Urol., 2004; 46: 80-87.

28. Morley J.E., Charlton E., Patrick P., Kaiser F.E., Cadeau P., McCready D., Perry H.M. III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.

29. Tancredi A., Reginster J.Y., Schleich F., Pire G., Maassen P., Luyckx F., Legros J.J. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers // Eur. J. Endocrinol. 2004; 151: 355-360.

30. Beutel M.E., Wiltink J., Hauck E.W., Auch D., Behre H.M., Brahler E., Weidner W. Correlations between hormones, physical, and affective parameters in aging urologic outpatients // Eur. Urol., 2005; 47: 749-755.

31. Diver M.J., Imtiaz K.E., Ahmad A.M., Vora J.P., Fraser W.D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men // Clin. Endocrinol. (Oxf.), 2003; 58: 710-717.

32. Citron J.T., Ettinger B., Rubinoff H., Ettinger V.M., Minkoff J., Hom F., Kan P., Alloo R. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism // J. Urol., 1996; 155: 529-533.

33. Bunch T.J., Abraham D., Wang S., Meikle A.W. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction // Aging Male, 2002; 5: 38-46.

34. Rhoden E.L., Estrada C., Levine L., Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism // J. Urol., 2003; 170: 795-798.

35. Buvat J., Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy // J. Urol., 1997; 158: 1764-1767.

36. Araujo A.B., O'Donnell A., Brambilla D.J., Simpson W.B., Longcope C., Matsumoto A.M., McKinlay J.B. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study // J. Clin. Endocrinol. Metab., 2004; 89: 5920-5926.

37. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J. Endocrinol. Invest., 2005; 28: 28-31.

38. Rosner W., Auchus R.J., Azziz R., Sluss P.M., Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement // J. Clin. Endocrinol. Metab., 2007; 92: 405-413.

39. Sikaris K., McLachlan R.I., Kazlauskas R. de K.D., Holden C.A., Handelsman D.J. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays // J. Clin. Endocrinol. Metab., 2005; 90: 5928-5936.

40. Taieb J., Mathian B., Millot F., Patricot M.C., Mathieu E., Queyrel N., Lacroix I., Somma-Delpero C., Boudou P. Testosterone measured by 10 immunoassays and by isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women, and children // Clin. Chem., 2003; 49: 1381-1395.

41. Wang C., Catlin D.H., Demers L.M., Starcevic B., Swerdloff R.S. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry // J. Clin. Endocrinol. Metab., 2004; 89: 534-543.

42. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum // J. Clin. Endocrinol. Metab., 1999; 84: 3666-3672.

43. Swerdloff R.S., Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence // Clin. Chem., 2008; 54: 458-460.

44. Rosner W. Errors in the measurement of plasma free testosterone // J. Clin. Endocrinol. Metab., 1997; 82: 2014-2015.

45. Wang C., Plymate S., Nieschlag E., Paulsen C.A. Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone // J. Clin. Endocrinol. Metab., 1981; 53: 1021-1024.

46. Allan C.A., Strauss B.J., Burger H.G., Forbes E.A., McLachlan R.I. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men // J. Clin. Endocrinol. Metab., 2008; 93: 139-146.

47. Meier C., Nguyen T.V., Handelsman D.J., Schindler C., Kushnir M.M., Rockwood A.L., Meikle A.W., Center J.R., Eisman J.A., Seibel M.J. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study // Arch. Intern. Med., 2008; 168: 47-54.

48. Kenny A.M., Prestwood K.M., Raisz L.G. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels // Endocr. Res., 2000; 26: 153-168.

49. Freitas S.S., Barrett-Connor E., Ensrud K.E., Fink H.A., Bauer D.C., Cawthon P.M., Lambert L.C., Orwoll E.S. Rate and circumstances of clinical vertebral fractures in older men // Osteoporos. Int., 2007; 19: 615-623.

50. Schousboe J.T., Taylor B.C., Fink H.A., Kane R.L., Cummings S.R., Orwoll E.S., Melton L.J. III, Bauer D.C., Ensrud K.E. Costeffectiveness of bone densitometry followed by treatment of osteoporosis in older men // JAMA, 2007; 298: 629-637.

51. Morales A., Buvat J., Gorren L.J., Guay A.T., Kaufman J.M., Tan H.M., Torres L.O. Endocrine aspects of sexual dysfunction in men // J. Sex. Med., 2004; 1: 69-81.

52. Black A.M., Day A.G., Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? // BJU Int, 2004; 94: 1066-1070.

53. Shabsigh R., Kaufman J.M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone // J. Urol., 2004; 172: 658-663.

54. Greenstein A., Mabjeesh N.J., Sofer M., Kaver I., Matzkin H., Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? // J. Urol., 2005; 173: 530-532.

55. Allen N.E., Appleby P.N., Davey G.K., Key T.J. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men // Cancer. Causes. Control, 2002; 13: 353-363.

56. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men // Curr. Opin. Endocrinol. Diabetes. Obes., 2007; 14: 226-234.

57. Selvin E., Feinleib M., Zhang L., Rohrmann S., Rifai N., Nelson W.G., Dobs A., Basaria S., Golden S.H., Platz E.A. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III) // Diabetes Care, 2007; 30: 234-238.

58. Rodriguez A., Muller D.C., Metter E.J., Maggio M., Harman S.M., Blackman M.R., Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging // J. Clin. Endocrinol. Metab., 2007; 92: 3568-3572.

59. Derby C.A., Zilber S., Brambilla D., Morales K.H., McKinlay J.B. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study // Clin. Endocrinol. (Oxf.), 2006; 65: 125-131.

60. Kapoor D., Aldred H., Clark S., Channer K.S., Jones T.H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity // Diabetes Care, 2007; 30: 911-917.

61. Kupelian V., Page S.T., Araujo A.B., Travison T.G., Bremner W.J., McKinlay J.B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men // J. Clin. Endocrinol. Metab., 2006; 91: 843-850.

62. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., Salonen R., Salonen J.T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men // Diabetes Care, 2004; 27: 1036-1041.

63. Kapoor D., Goodwin E., Channer K.S., Jones T.H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes // Eur. J. Endocrinol., 2006; 154: 899-906.

64. Corrales J.J., Burgo R.M., Garca-Berrocal B., Almeida M., Alberca I., Gonzalez-Buitrago J.M., Orfao A., Miralles J.M. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control // Metabolism, 2004; 53: 666-672.

65. Basu R., Dalla M.C., Campioni M., Basu A., Nair K.S., Jensen M.D., Khosla S., Klee G., Toffolo G., Cobelli C., Rizza R.A. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men // Diabetes Care, 2007; 30: 1972-1978.

66. Roddam A.W., Allen N.E., Appleby P., Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies // J. Natl. Cancer. Inst., 2008; 100: 170-183.

67. Carpenter W.R., Robinson W.R., Godley P.A. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer // J. Natl. Cancer. Inst., 2008; 100: 158-159.

68. Fowler J.E. Jr., Whitmore W.F. Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer // Cancer, 1982; 49: 1373-1377.

69. McConnell J.D. Prostatic growth: new insights into hormonal regulation // Br. J. Urol., 1995; 76: 5-10.

70. Parekh D.J., Ankerst D.P., Higgins B.A., Hernandez J., Canby-Hagino E., Brand T., Troyer D.A., Leach R.J., Thompson I.M. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population // Urology, 2006; 68: 1152-1155.

71. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., Feng Z., Parnes H.L., Coltman C.A. Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial // J. Natl. Cancer. Inst., 2006; 98: 529-534.

72. Thompson I.M., Carroll P.R., Carducci M.A. Recommendations for defining and treating high risk localized prostate cancer // J. Urol., 2006; 176: S6-S10.

73. Marks L.S., Mazer N.A., Mostaghel E., Hess D.L., Dorey F.J., Epstein J.I., Veltri R.W., Makarov D.V., Partin A.W., Bostwick D.G., Macairan M.L., Nelson P.S. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial // JAMA, 2006; 296: 2351-2361.

74. Meikle A.W., Arver S., Dobs A.S., Adolfsson J., Sanders S.W., Middleton R.G., Stephenson R.A., Hoover D.R., Rajaram L., Mazer N.A. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system // Urology, 1997; 49: 191-196.

75. Bhasin S., Singh A.B., Mac R.P., Carter B., Lee M.I., Cunningham G.R. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan // J. Androl., 2003; 24: 299-311.

76. Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring // N. Engl. J. Med., 2004; 350: 482-492.

77. Agarwal P.K., Oefelein M.G. Testosterone replacement therapy after primary treatment for prostate cancer // J. Urol., 2005; 173: 533-536.

78. Kaufman J.M., Graydon R.J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men // J. Urol., 2004; 172: 920-922.

79. Khera M., Lipshultz L.I. The role of testosterone replacement therapy following radical prostatectomy // Urol. Clin. North. Am., 2007; 34: 549-553, vi.

80. Sarosdy M.F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy // Cancer, 2007; 109: 536-541.

81. Nieschlag E., Behre H.M. Testosterone: Action, Deficiency, Substitution. 3rd edn. Cambridge: Cambridge University Press; 2004.

82. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men // Clin. Endocrinol. (Oxf.), 2006; 65: 275-281.

83. Calof O.M., Singh A.B., Lee M.L., Kenny A.M., Urban R.J., Tenover J.L., Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials // J. Gerontol. A. Biol. Sci. Med. Sci., 2005; 60: 1451-1457.

84. Parsons J.K., Carter H.B., Platz E.A., Wright E.J., Landis P., Metter E.J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy // Cancer. Epidemiol. Biomarkers. Prev., 2005; 14: 2257-2260.

85. Zitzmann M., Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men // J. Clin. Endocrinol. Metab., 2007; 92: 3844-3853.

86. Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., Channer K.S. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial // Eur. Heart. J., 2006; 27: 57-64.

87. Hanafy H.M. Testosterone therapy and obstructive sleep apnea: is there a real connection? // J. Sex. Med., 2007; 4: 1241-1246.

88. Drinka P.J., Jochen A.L., Cuisinier M., Bloom R., Rudman I., Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels // J. Am. Geriatr. Soc., 1995; 43: 899-901.